1. Show article details.

    BRIEF-Bluebird Bio Inc - Anticipates That Cash, Cash Equivalents, Marketable Securities Were About $1.3 Bln As Of December 31, 2020

    Reuters – 8:16 AM ET 01/11/2021

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO INC (BLUE) - ANTICIPATES THAT CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES WERE ABOUT $1.3 BILLION AS OF DECEMBER 31, 2020 Source text for Eikon: [https://bit.ly/35wGGDf] Further company coverage:

  2. Show article details.

    BRIEF-Bluebird Bio To Separate Oncology Business Into Independent Company

    Reuters – 7:11 AM ET 01/11/2021

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO TO SEPARATE ONCOLOGY BUSINESS INTO INDEPENDENT COMPANY. * BLUEBIRD BIO INC (BLUE) - SEVERE GENETIC DISEASE BUSINESS WILL REMAIN FOCUS OF BLUEBIRD BIO (BLUE), INC. * BLUEBIRD BIO INC (BLUE) - COMPANY ANNOUNCES CEO AND CHAIR OF BOARD FOR EACH FUTURE ENTITY. * BLUEBIRD BIO INC (BLUE) - SEPARATION EXPECTED TO RESULT IN TWO INDEPENDENT, PUBLICLY TRADED COMPANIES BY YEAR-END 2021.

  3. Show article details.

    Bluebird to spin off cancer drugs unit to focus on genetic diseases

    Reuters – 6:58 AM ET 01/11/2021

    Bluebird bio Inc (BLUE) said on Monday it plans to spin off its cancer drugs unit into a new, publicly traded company later this year to focus on rare genetic diseases. The gene therapy developer suffered multiple regulatory setbacks last year for both its rare disease and cancer drug candidates.

  4. Show article details.

    bluebird bio to Separate Oncology Business into Independent Company

    Business Wire – 6:30 AM ET 01/11/2021

    Severe Genetic Disease business will remain the focus of bluebird bio, Inc.; separation expected to result in two independent, publicly traded companies by year-end 2021 Separation designed to unlock value through improved operational execution, organizational focus, tailored capital allocation, and enhanced strategic optionality Company announces CEO and Chair of the Board for each future enti...

  5. Show article details.

    Bluebird bio to spin off cancer drugs unit - WSJ

    Reuters – 6:25 AM ET 01/11/2021

    Bluebird bio Inc (BLUE) plans to spin off its cancer drugs unit into a new, publicly traded company later this year, the Wall Street Journal reported on Monday.

  6. Show article details.

    BRIEF-Bluebird Bio To Spin Off Cancer-Drug Unit- WSJ

    Reuters – 5:36 AM ET 01/11/2021

    * BLUEBIRD BIO TO SPIN OFF CANCER-DRUG UNIT- WSJ Source text: https://on.wsj.com/3otE0h3.

  7. Show article details.

    BRIEF-Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., As Chief Medical Officer

    Reuters – 9:28 AM ET 01/06/2021

    Verastem Inc (VSTM): * VERASTEM ONCOLOGY APPOINTS FRANK NEUMANN, M.D., PH.D., AS CHIEF MEDICAL OFFICER. * Verastem Inc (VSTM) - FRANK NEUMANN JOINS VERASTEM FROM BLUEBIRD BIO Source text for Eikon: Further company coverage:

  8. Show article details.

    Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officer

    Business Wire – 8:00 AM ET 12/08/2020

    Shape Therapeutics, Inc., a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment of Gary Fortin as Chief Operating Officer.

  9. Show article details.

    BRIEF-Bluebird Bio Inc Announces New Data From Group C Of Its Ongoing Phase 1/2 Hgb-206 Study Of Investigational Lentiglobin Gene Therapy

    Reuters – 5:45 PM ET 12/07/2020

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO INC (BLUE) - ANNOUNCED NEW DATA FROM GROUP C OF ITS ONGOING PHASE 1/2 HGB-206 STUDY OF INVESTIGATIONAL LENTIGLOBIN GENE THERAPY. * BLUEBIRD BIO (BLUE) - INVESTIGATIONAL LENTIGLOBIN GENE THERAPY STUDY SHOWED COMPLETE ELIMINATION OF SEVERE VOES AND VOES BETWEEN 6 - 24 MONTHS OF FOLLOW-UP Source text for Eikon: Further company coverage:

  10. Show article details.

    Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting

    Business Wire – 4:30 PM ET 12/07/2020

    No severe vaso-occlusive events reported through 24 months of follow-up in Group C patients who had a history of at least four severe VOEs and at least six months of follow-up At up to 30 months follow-up and 32 patients treated, Group C patients continue to produce consistent levels of gene therapy-derived anti-sickling hemoglobin, reducing levels of abnormal sickle hemoglobin that cause symp...

  11. Show article details.

    BRIEF-bluebird bio's Updated Long-Term Efficacy,Safety Results Reflecting Up To 6 Years Of Data For Betibeglogene Autotemcel Gene Therapy In Patients With TDT

    Reuters – 8:28 PM ET 12/05/2020

    bluebird bio Inc: * BLUEBIRD BIO-UPDATED LONG-TERM EFFICACY,SAFETY RESULTS REFLECTING UP TO 6 YEARS OF DATA FOR BETIBEGLOGENE AUTOTEMCEL GENE THERAPY IN PATIENTS WITH TDT. * BLUEBIRD BIO (BLUE)- ALL PATIENTS WHO ACHIEVED TRANSFUSION INDEPENDENCE CONTINUE TO REMAIN TRANSFUSION FREE IN ONGOING LONG-TERM FOLLOW-UP STUDY Source text for Eikon: Further company coverage:

  12. Show article details.

    Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting

    Business Wire – 3:00 PM ET 12/05/2020

    All patients who achieved transfusion independence continue to remain transfusion free in ongoing long-term follow-up study 87% of pediatric patients in Phase 3 studies achieved transfusion independence with median weighted average hemoglobin of 11.3 g/dL​ and remain transfusion free In long-term follow-up, 53% of patients who achieved transfusion independence and restarted iron chelation hav...

  13. Show article details.

    Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

    Business Wire – 12:30 PM ET 12/05/2020

    Longer-term data from Phase 1 CRB-401 study evaluating ide-cel in relapsed and refractory multiple myeloma show ongoing deep and durable responses and median overall survival of 34.2 months1 Analyses from pivotal KarMMa study show clinically meaningful health-related quality of life benefits with ide-cel and underscore the potential value of ide-cel in elderly patients and in patients with high...

  14. Show article details.

    BRIEF-Magenta Therapeutics, Bluebird Bio Announce Phase 2 Clinical Trial Collaboration To Evaluate Magenta’S MGTA

    Reuters – 8:07 AM ET 12/04/2020

    bluebird bio Inc: * MAGENTA THERAPEUTICS AND BLUEBIRD BIO ANNOUNCE A PHASE 2 CLINICAL TRIAL COLLABORATION TO EVALUATE MAGENTA’S MGTA-145 FOR MOBILIZING AND COLLECTING STEM CELLS IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE Source text for Eikon: Further company coverage:

  15. Show article details.

    Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

    Business Wire – 8:00 AM ET 12/04/2020

    Magenta Therapeutics (MGTA) and bluebird bio, Inc. today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. This press release features multimedia.

  16. Show article details.

    bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

    Business Wire – 8:00 AM ET 11/24/2020

    bluebird bio, Inc. today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition. Investors may listen to the call by dialing 825-4408 from locations in the United States or +1 625-3227 from outside the United States.

  17. Show article details.

    bluebird bio Announces November Investor Events

    Business Wire – 8:00 AM ET 11/10/2020

    bluebird bio, Inc. today announced that members of the management team will participate in the following upcoming investor conferences: To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on t...

  18. Show article details.

    bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

    Business Wire – 7:30 AM ET 11/05/2020

    Updated results from ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin™ for sickle cell disease gene therapy Long-term efficacy and safety results for betibeglogene autotemcel gene therapy in adult and pediatric patients with beta-thalassemia across genotypes Updated safety and efficacy results from ongoing studies of idecabtagene vicleucel and bb21217 in multiple myeloma CAMBRIDGE, Mass.

  19. Show article details.

    Bristol Myers Squibb Reports Third Quarter 2020 Financial Results

    Business Wire – 6:59 AM ET 11/05/2020

    NEW YORK---- Bristol Myers Squibb (BMY) today reports results for the third quarter of 2020, which reflect strong product sales, continued pipeline advancement and robust operating performance.

  20. Show article details.

    BRIEF-Bluebird Bio Reports Third Quarter 2020 Financial Results And Highlights Operational Progress

    Reuters – 4:20 PM ET 11/04/2020

    bluebird bio Inc: * BLUEBIRD BIO REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS. * Q3 REVENUE $19.3 MILLION VERSUS $8.9 MILLION. * Q3 REVENUE ESTIMATE $24.2 MILLION -- REFINITIV IBES DATA.

Page:

Today's and Upcoming Events

  • Feb
    16

    BLUE to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    04

    BLUE announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.